James Daly Buys Shares of Madrigal Pharmaceuticals, Inc. $MDGL
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
James Daly, insider at Madrigal Pharmaceuticals, Inc. ($MDGL), bought 766 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Madrigal Pharmaceuticals, Inc. Stock Down 5.2%
Shares of Madrigal Pharmaceuticals, Inc. ($MDGL) traded around $505.75 on Thursday, down 5.2% for the day.
Madrigal Pharmaceuticals, Inc. Earnings
Analysts Set New Price Targets
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Get Madrigal Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $MDGL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.